Access Statistics for Paolo Pertile

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 0 0 0 182 2 3 3 376
DRGs: the link between investment in technologies and appropriateness 0 0 0 27 0 0 2 122
Dynamic, economic approaches to HTA under uncertainty 0 0 0 45 0 0 1 172
Dynamic, incentive-compatible contracting for health services 0 0 0 7 1 1 2 14
Dynamic, incentive-compatible contracting for health services 0 1 1 11 0 1 3 10
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 1 2 2 154 3 7 11 393
Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation 0 0 0 58 1 1 3 155
L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC 0 0 2 20 0 2 4 112
Modelling life-course decisions for the analysis of interpersonal and intrapersonal redistribution 0 0 0 18 0 0 1 154
Optimal sequential sampling rules for the economic evaluation of health technologies 0 0 0 86 0 0 2 251
Pricing policies when patients are heterogeneous: a welfare analysis 0 0 0 17 0 1 3 54
Public finance consolidation and fairness across living generations: the case of Italy 0 0 0 70 0 0 3 186
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 0 0 1 64 0 2 4 105
R&D and market size: who benefits from orphan drug regulation? 0 0 1 76 0 1 5 197
Redistribution at the Local Level: The Case of Public Childcare in Italy 0 0 0 37 1 1 4 132
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 0 1 2 24 0 1 4 66
Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules 0 0 0 40 0 0 2 129
The dynamics of pharmaceutical regulation and R&D investments 0 0 0 77 0 0 2 219
Who should monitor job sick leave? 0 0 0 28 0 1 4 115
Total Working Papers 1 4 9 1,041 8 22 63 2,962


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Bayesian decision theoretic model of sequential experimentation with delayed response 0 0 0 3 0 0 1 31
A large scale OLG model for the analysis of the redistributive effects of policy reforms 0 0 2 43 3 4 7 134
A reply to “Who would benefit from average value‐based pricing?” 1 1 1 4 1 1 1 20
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 0 0 0 16 0 0 0 86
Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition” 0 0 0 3 1 1 2 28
Investment in Health Technologies in a Competitive Model with Real Options 0 0 0 34 0 0 2 110
Job sick leave: Detecting opportunistic behavior 0 0 2 8 1 2 6 35
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation 0 0 1 9 1 2 3 61
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 0 0 1 18 0 0 2 63
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective 0 0 1 17 2 3 5 66
R&D and market size: Who benefits from orphan drug legislation? 0 0 0 4 1 1 5 31
Redistribution at the local level: the case of public childcare in Italy 0 0 0 4 0 0 4 53
Static and dynamic efficiency of irreversible health care investments under alternative payment rules 0 0 0 21 0 0 2 147
Technology adoption, quality and health care costs: a review of the literature 0 0 0 4 0 0 1 31
The Dynamics of Pharmaceutical Regulation and R&D Investments 0 1 1 10 0 1 2 64
The fiscal disadvantage of young Italians: a new view on consolidation and fairness 0 0 3 33 0 2 15 201
The impact of managed entry agreements on pharmaceutical prices 0 0 2 15 3 5 10 82
The timing of adoption of positron emission tomography: a real options approach 0 0 0 18 0 0 1 87
Two-part payments for the reimbursement of investments in health technologies 0 0 0 13 0 0 2 53
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 0 1 1 9 0 1 3 52
Which valued‐based price when patients are heterogeneous? 0 0 0 12 1 1 1 39
Total Journal Articles 1 3 15 298 14 24 75 1,474


Statistics updated 2025-08-05